Skip to main content
Top
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Classification tree analysis to enhance targeting for follow-up exam of colorectal cancer screening

Authors: Yoshiki Ishikawa, Ying-Fang Zheng, Hiromu Nishiuchi, Takeo Suda, Tadahiko Hasumi, Hiroshi Saito

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

Follow-up rate after a fecal occult blood test (FOBT) is low worldwide. In order to increase the follow-up rate, segmentation of the target population has been proposed as a promising strategy, because an intervention can then be tailored toward specific subgroups of the population rather than using one type of intervention for all groups. The aim of this study is to identify subgroups that share the same patterns of characteristics related to follow-up exams after FOBT.

Methods

The study sample consisted of 143 patients aged 50–69 years who were requested to undergo follow-up exams after FOBT. A classification tree analysis was performed, using the follow-up rate as a dependent variable and sociodemographic variables, psychological variables, past FOBT and follow-up exam, family history of colorectal cancer (CRC), and history of bowel disease as predictive variables.

Results

The follow-up rate in 143 participants was 74.1% (n = 106). A classification tree analysis identified four subgroups as follows; (1) subgroup with a high degree of fear of CRC, unemployed and with a history of bowel disease (n = 24, 100.0% follow-up rate), (2) subgroup with a high degree of fear of CRC, unemployed and with no history of bowel disease (n = 17, 82.4% follow-up rate), (3) subgroup with a high degree of fear of CRC and employed (n = 24, 66.7% follow-up rate), and (4) subgroup with a low degree of fear of CRC (n = 78, 66.7% follow-up rate).

Conclusion

The identification of four subgroups with a diverse range of follow-up rates for CRC screening indicates the direction to take in future development of an effective tailored intervention strategy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.CrossRefPubMed
2.
go back to reference Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996, 348: 1472-1477. 10.1016/S0140-6736(96)03386-7.CrossRefPubMed Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM: Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996, 348: 1472-1477. 10.1016/S0140-6736(96)03386-7.CrossRefPubMed
3.
go back to reference Jorgensen OD, Kronborg O, Fenger C: A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut. 2002, 50: 29-32. 10.1136/gut.50.1.29.CrossRefPubMedPubMedCentral Jorgensen OD, Kronborg O, Fenger C: A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and seven biennial screening rounds. Gut. 2002, 50: 29-32. 10.1136/gut.50.1.29.CrossRefPubMedPubMedCentral
4.
go back to reference Mandel JS, Church TR, Ederer F, Bond JH: Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999, 91: 434-437. 10.1093/jnci/91.5.434.CrossRefPubMed Mandel JS, Church TR, Ederer F, Bond JH: Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999, 91: 434-437. 10.1093/jnci/91.5.434.CrossRefPubMed
5.
go back to reference Hewitson P, Glasziou P, Irwig L, Towler B, Watson E: Screening for colorectal cancer using the faecal occult blood test. Hemoccult. Cochrane Database Syst Rev. 2007, 24: CD001216-10.1002/14651858.CD001216.pub2 Hewitson P, Glasziou P, Irwig L, Towler B, Watson E: Screening for colorectal cancer using the faecal occult blood test. Hemoccult. Cochrane Database Syst Rev. 2007, 24: CD001216-10.1002/14651858.CD001216.pub2
6.
go back to reference Saito H, Soma Y, Koeda J, Wada T, Kawaguchi H, Sobue T, Aisawa T, Yoshida Y: Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case–control study. Int J Cancer. 1995, 61: 465-469. 10.1002/ijc.2910610406.CrossRefPubMed Saito H, Soma Y, Koeda J, Wada T, Kawaguchi H, Sobue T, Aisawa T, Yoshida Y: Reduction in risk of mortality from colorectal cancer by fecal occult blood screening with immunochemical hemagglutination test. A case–control study. Int J Cancer. 1995, 61: 465-469. 10.1002/ijc.2910610406.CrossRefPubMed
7.
go back to reference Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM: The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000, 343: 1603-1607. 10.1056/NEJM200011303432203.CrossRefPubMed Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM: The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000, 343: 1603-1607. 10.1056/NEJM200011303432203.CrossRefPubMed
8.
go back to reference Kaye JA, Shulman LN: Screening program for colorectal cancer: participation and follow up. HMO Pract. 1991, 5: 168-170.PubMed Kaye JA, Shulman LN: Screening program for colorectal cancer: participation and follow up. HMO Pract. 1991, 5: 168-170.PubMed
9.
go back to reference Morris JB, Stellato TA, Guy BB, Gordon NH, Berger NA: A critical analysis of the largest reported mass fecal occult blood screening program in the United States. Am J Surg. 1991, 161: 101-105. 10.1016/0002-9610(91)90368-N.CrossRefPubMed Morris JB, Stellato TA, Guy BB, Gordon NH, Berger NA: A critical analysis of the largest reported mass fecal occult blood screening program in the United States. Am J Surg. 1991, 161: 101-105. 10.1016/0002-9610(91)90368-N.CrossRefPubMed
10.
go back to reference Myers RE, Balshem AM, Wolf TA, Ross EA, Millner L: Screening for colorectal neoplasia: physicians’ adherence to complete diagnostic evaluation. Am J Public Health. 1993, 83: 1620-1622. 10.2105/AJPH.83.11.1620.CrossRefPubMedPubMedCentral Myers RE, Balshem AM, Wolf TA, Ross EA, Millner L: Screening for colorectal neoplasia: physicians’ adherence to complete diagnostic evaluation. Am J Public Health. 1993, 83: 1620-1622. 10.2105/AJPH.83.11.1620.CrossRefPubMedPubMedCentral
11.
go back to reference Levin B, Hess K, Johnson C: Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med. 1997, 157: 970-976. 10.1001/archinte.1997.00440300064005.CrossRefPubMed Levin B, Hess K, Johnson C: Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med. 1997, 157: 970-976. 10.1001/archinte.1997.00440300064005.CrossRefPubMed
12.
go back to reference Lurie JD, Welch HG: Diagnostic testing following fecal occult blood screening in the elderly. J Natl Cancer Inst. 1999, 91: 1641-1646. 10.1093/jnci/91.19.1641.CrossRefPubMed Lurie JD, Welch HG: Diagnostic testing following fecal occult blood screening in the elderly. J Natl Cancer Inst. 1999, 91: 1641-1646. 10.1093/jnci/91.19.1641.CrossRefPubMed
13.
go back to reference Sharma VK, Vasudeva R, Howden CW: Colorectal cancer screening and surveillance practices by primary care physicians: results of a national survey. Am J Gastroenterol. 2000, 95: 1551-1556. 10.1111/j.1572-0241.2000.02093.x.CrossRefPubMed Sharma VK, Vasudeva R, Howden CW: Colorectal cancer screening and surveillance practices by primary care physicians: results of a national survey. Am J Gastroenterol. 2000, 95: 1551-1556. 10.1111/j.1572-0241.2000.02093.x.CrossRefPubMed
14.
go back to reference Shield HM, Weiner MS, Henry DR, Lloyd JA, Ransil BJ, Lamphier DA, Gallagher DW, Antonioli DA, Rosner BA: Factors that influence the decision to do an adequate evaluation of a patient with a positive stool for occult blood. Am J Gastroenterol. 2001, 96: 196-203. 10.1111/j.1572-0241.2001.03475.x.CrossRef Shield HM, Weiner MS, Henry DR, Lloyd JA, Ransil BJ, Lamphier DA, Gallagher DW, Antonioli DA, Rosner BA: Factors that influence the decision to do an adequate evaluation of a patient with a positive stool for occult blood. Am J Gastroenterol. 2001, 96: 196-203. 10.1111/j.1572-0241.2001.03475.x.CrossRef
15.
go back to reference Myers RE, Turner B, Weinberg D, Hyslop T, Hauck WW, Brigham T, Rothermel T, Grana J, Schlackman N: Impact of a physician oriented intervention on follow-up in colorectal cancer screening. Prev Med. 2002, 137: 132-141. Myers RE, Turner B, Weinberg D, Hyslop T, Hauck WW, Brigham T, Rothermel T, Grana J, Schlackman N: Impact of a physician oriented intervention on follow-up in colorectal cancer screening. Prev Med. 2002, 137: 132-141.
16.
go back to reference Ko CW, Dominitz JA, Nguyen TD: Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am J Med. 2003, 115: 111-114.CrossRefPubMed Ko CW, Dominitz JA, Nguyen TD: Fecal occult blood testing in a general medical clinic: comparison between guaiac-based and immunochemical-based tests. Am J Med. 2003, 115: 111-114.CrossRefPubMed
17.
go back to reference Turner B, Myers RE, Hyslop T, Hauck WW, Weinberg D, Brigham T, Grana J, Rothermel T, Schlackman N: Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. J Gen Intern Med. 2003, 18: 357-363. 10.1046/j.1525-1497.2003.20525.x.CrossRefPubMedPubMedCentral Turner B, Myers RE, Hyslop T, Hauck WW, Weinberg D, Brigham T, Grana J, Rothermel T, Schlackman N: Physician and patient factors associated with ordering a colon evaluation after a positive fecal occult blood test. J Gen Intern Med. 2003, 18: 357-363. 10.1046/j.1525-1497.2003.20525.x.CrossRefPubMedPubMedCentral
18.
go back to reference Baig N, Myers RE, Turner BJ, Grana J, Rothermel T, Schlackman N, Weinberg DS: Physician reported reasons for limited follow-up of patients with a positive fecal occult blood test screening result. Am J Gastroenterol. 2003, 98: 2078-2081. 10.1111/j.1572-0241.2003.07575.x.CrossRefPubMed Baig N, Myers RE, Turner BJ, Grana J, Rothermel T, Schlackman N, Weinberg DS: Physician reported reasons for limited follow-up of patients with a positive fecal occult blood test screening result. Am J Gastroenterol. 2003, 98: 2078-2081. 10.1111/j.1572-0241.2003.07575.x.CrossRefPubMed
19.
go back to reference Nadel MR, Shapiro JA, Klabunde CN, Seeff LC, Uhler R, Smith RA, Ransohoff DF: A national survey of primary care physicians’ methods for screening for fecal occult blood. Ann Intern Med. 2005, 142: 86-94. 10.7326/0003-4819-142-2-200501180-00007.CrossRefPubMed Nadel MR, Shapiro JA, Klabunde CN, Seeff LC, Uhler R, Smith RA, Ransohoff DF: A national survey of primary care physicians’ methods for screening for fecal occult blood. Ann Intern Med. 2005, 142: 86-94. 10.7326/0003-4819-142-2-200501180-00007.CrossRefPubMed
20.
go back to reference Etzioni DA, Yano EM, Rubenstein LV, Lee ML, Ko CY, Brook RH, Parkerton PH, Asch SM: Measuring the quality of colorectal cancer screening: the importance of follow-up. Dis Colon Rectum. 2006, 49: 1002-1010. 10.1007/s10350-006-0533-2.CrossRefPubMed Etzioni DA, Yano EM, Rubenstein LV, Lee ML, Ko CY, Brook RH, Parkerton PH, Asch SM: Measuring the quality of colorectal cancer screening: the importance of follow-up. Dis Colon Rectum. 2006, 49: 1002-1010. 10.1007/s10350-006-0533-2.CrossRefPubMed
21.
go back to reference Fisher DA, Jeffreys A, Coffman CJ, Fasanella K: Barriers to full colon evaluation for a positive fecal occult blood test. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1232-1235. 10.1158/1055-9965.EPI-05-0916.CrossRefPubMed Fisher DA, Jeffreys A, Coffman CJ, Fasanella K: Barriers to full colon evaluation for a positive fecal occult blood test. Cancer Epidemiol Biomarkers Prev. 2006, 15: 1232-1235. 10.1158/1055-9965.EPI-05-0916.CrossRefPubMed
22.
go back to reference Garman KS, Jeffreys A, Coffman C, Fisher DA: Colorectal cancer screening, comorbidity, and follow-up in elderly patients. Am J Med Sci. 2006, 332: 159-163. 10.1097/00000441-200610000-00001.CrossRefPubMed Garman KS, Jeffreys A, Coffman C, Fisher DA: Colorectal cancer screening, comorbidity, and follow-up in elderly patients. Am J Med Sci. 2006, 332: 159-163. 10.1097/00000441-200610000-00001.CrossRefPubMed
23.
go back to reference Miglioretti DL, Rutter CM, Bradford SC, Zauber AG, Kessler LG, Feuer EJ, Grossman DC: Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care. 2008, 46 (Suppl 1): 91-96.CrossRef Miglioretti DL, Rutter CM, Bradford SC, Zauber AG, Kessler LG, Feuer EJ, Grossman DC: Improvement in the diagnostic evaluation of a positive fecal occult blood test in an integrated health care organization. Med Care. 2008, 46 (Suppl 1): 91-96.CrossRef
24.
go back to reference Jimbo M, Myers RE, Meyer B, Hyslop T, Cocroft J, Turner BJ, Weinberg DS: Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Ann Fam Med. 2009, 7: 11-16. 10.1370/afm.906.CrossRefPubMedPubMedCentral Jimbo M, Myers RE, Meyer B, Hyslop T, Cocroft J, Turner BJ, Weinberg DS: Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Ann Fam Med. 2009, 7: 11-16. 10.1370/afm.906.CrossRefPubMedPubMedCentral
25.
go back to reference Slater MD: Theory and method in health audience segmentation. J Health Commun. 1996, 1: 267-283. 10.1080/108107396128059.CrossRefPubMed Slater MD: Theory and method in health audience segmentation. J Health Commun. 1996, 1: 267-283. 10.1080/108107396128059.CrossRefPubMed
26.
go back to reference Holt CL, Shipp M, Eloubeidi M, Clay KS, Smith-Janas MA, Janas MJ, Britt K, Norena M, Fouad MN: Use of focus group data to develop recommendations for demographically segmented colorectal cancer educational strategies. Health Educ Res. 2009, 24: 876-889. 10.1093/her/cyp024.CrossRefPubMed Holt CL, Shipp M, Eloubeidi M, Clay KS, Smith-Janas MA, Janas MJ, Britt K, Norena M, Fouad MN: Use of focus group data to develop recommendations for demographically segmented colorectal cancer educational strategies. Health Educ Res. 2009, 24: 876-889. 10.1093/her/cyp024.CrossRefPubMed
27.
go back to reference Albada A, Ausems MGEM, Bensing JM, Van Dulmen S: Tailored information about cancer risk and screening: a systematic review. Patient Educ Couns. 2009, 77: 155-171. 10.1016/j.pec.2009.03.005.CrossRefPubMed Albada A, Ausems MGEM, Bensing JM, Van Dulmen S: Tailored information about cancer risk and screening: a systematic review. Patient Educ Couns. 2009, 77: 155-171. 10.1016/j.pec.2009.03.005.CrossRefPubMed
28.
go back to reference Rosenstock IM: Historical origins of the health belief model. Health Educ Monogr. 1974, 1: 8- Rosenstock IM: Historical origins of the health belief model. Health Educ Monogr. 1974, 1: 8-
29.
go back to reference Ajzen I: From intentions to actions: a theory of planned behavior. Action control: from cognition to behavior. Edited by: Kuhl J, Beckmann J. 1985, Berlin: Springer-Verlag, 11-39.CrossRef Ajzen I: From intentions to actions: a theory of planned behavior. Action control: from cognition to behavior. Edited by: Kuhl J, Beckmann J. 1985, Berlin: Springer-Verlag, 11-39.CrossRef
30.
go back to reference Kiviniemi MT, Alyssa B, Marie Z, Marshal JR: Individual-level factors in colorectal cancer screening: a review of the literature on the relation of individual level health behavior constructs and screening behavior. Psychooncology. 2011, 20: 1023-1033. 10.1002/pon.1865.CrossRefPubMed Kiviniemi MT, Alyssa B, Marie Z, Marshal JR: Individual-level factors in colorectal cancer screening: a review of the literature on the relation of individual level health behavior constructs and screening behavior. Psychooncology. 2011, 20: 1023-1033. 10.1002/pon.1865.CrossRefPubMed
31.
go back to reference Sutton SR, Wardle J, Taylor T, McCaffery K, Williamson S, Edwards R, Cuzick J, Hart A, Northover J, Atkin W: Predictors of attendance in the United Kingdom flexible sigmoidoscopy screening trail. J Med Screen. 2000, 99: 104- Sutton SR, Wardle J, Taylor T, McCaffery K, Williamson S, Edwards R, Cuzick J, Hart A, Northover J, Atkin W: Predictors of attendance in the United Kingdom flexible sigmoidoscopy screening trail. J Med Screen. 2000, 99: 104-
32.
go back to reference Watts BG, Vernon SW, Myers RE, Tilley BC: Intention to be screened over time for colorectal cancer in male automotive workers. Cancer Epidemiol Biomark Prev. 2003, 12: 339-349. Watts BG, Vernon SW, Myers RE, Tilley BC: Intention to be screened over time for colorectal cancer in male automotive workers. Cancer Epidemiol Biomark Prev. 2003, 12: 339-349.
33.
go back to reference Zheng YF, Saito T, Takahashi M, Ishibashi T, Kai I: Factors associated with intentions to adhere to colorectal cancer screening follow-up exams. BMC Public Health. 2006, 6: 272-10.1186/1471-2458-6-272.CrossRefPubMedPubMedCentral Zheng YF, Saito T, Takahashi M, Ishibashi T, Kai I: Factors associated with intentions to adhere to colorectal cancer screening follow-up exams. BMC Public Health. 2006, 6: 272-10.1186/1471-2458-6-272.CrossRefPubMedPubMedCentral
34.
go back to reference Kiernan M, Kraemer HC, Winkleby MA, King AC, Taylor CB: Do logistic regression and signal detection identify different subgroups at risk? Implications for the design of tailored interventions. Psychol Methods. 2001, 6: 35-48.CrossRefPubMed Kiernan M, Kraemer HC, Winkleby MA, King AC, Taylor CB: Do logistic regression and signal detection identify different subgroups at risk? Implications for the design of tailored interventions. Psychol Methods. 2001, 6: 35-48.CrossRefPubMed
35.
go back to reference Podgorelec V, Kokol P, Stiglic B, Rozman I: Decision trees: an overview and their use in medicine. J med Syst. 2002, 26: 445-463. 10.1023/A:1016409317640.CrossRefPubMed Podgorelec V, Kokol P, Stiglic B, Rozman I: Decision trees: an overview and their use in medicine. J med Syst. 2002, 26: 445-463. 10.1023/A:1016409317640.CrossRefPubMed
36.
go back to reference Glanz K, Bishop D: The role of behavioral science theory in development and implementation of public health interventions. Annu Rev Public Health. 2010, 31: 399-418. 10.1146/annurev.publhealth.012809.103604.CrossRefPubMed Glanz K, Bishop D: The role of behavioral science theory in development and implementation of public health interventions. Annu Rev Public Health. 2010, 31: 399-418. 10.1146/annurev.publhealth.012809.103604.CrossRefPubMed
Metadata
Title
Classification tree analysis to enhance targeting for follow-up exam of colorectal cancer screening
Authors
Yoshiki Ishikawa
Ying-Fang Zheng
Hiromu Nishiuchi
Takeo Suda
Tadahiko Hasumi
Hiroshi Saito
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-470

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine